BCP
ABUS icon

BlackBarn Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

BlackBarn Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Buy
2,500,000
+650,000
+35% +$2.84M 3.38% 17
2025
Q4 		$8.9M Sell
1,850,000
-150,000
-8% -$674K 3.19% 15
2025
Q3 		$9.08M Sell
2,000,000
-603,521
-23% -$2.22M 2.96% 18
2025
Q2 		$8.04M Buy
2,603,521
+261,650
+11% +$869K 2.67% 18
2025
Q1 		$8.17M Hold
2,341,871
– – 2.79% 16
2024
Q4 		$7.66M Buy
2,341,871
+270,971
+13% +$997K 3.01% 14
2024
Q3 		$7.97M Hold
2,070,900
– – 3.47% 14
2024
Q2 		$6.4M Hold
2,070,900
– – 3.3% 19
2024
Q1 		$5.34M Buy
+2,070,900
New +$5.36M 3.09% 14

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $2.17B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $329M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return